Astellas’ Veoza (fezolinetant) will soon be available to some women in the UK suffering from vasomotor symptoms (VMS) associated with menopause following approval by the Medicines and Healthcare Regulatory Agency (MHRA). Despite VMS, or hot flushes, being a common symptom of menopause, until now, hormone replacement therapy (HRT) was the only treatment. The drug will […]